The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,262% of patients treated with ...

Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...

Scientists have discovered how a mitochondrial mutation rewires immune function in a model of inherited primary mitochondrial ...

ORLANDO -- Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve durable disease control in the second-line setting while stopping daily ...

ITP is an autoimmune condition where the body’s immune cells mistakenly attack platelets, the blood cells responsible for clotting.

New phase 3 data showed that patients with primary immune thrombocytopenia saw improved disease control when ianalumab was ...

An evolutionary perspective on immune priming across plants and invertebrates highlights the roles of microbiomes and epigenetic regulation in shaping innate immune memory with promising applications ...

The scientists have discovered that a single inherited mutation causes whole-body issues in a model of inherited primary mitochondrial disorders after the immune response is sparked into action.

Scientists have discovered how a mitochondrial mutation rewires immune function in a model of inherited primary mitochondrial disorders, which often lead to severe disability and death.

Imvax has shrugged off the failure of its phase 2b brain cancer trial to hit its primary endpoint, reporting evidence of ...